2 completed, 1 not yet recruiting. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Not yet recruiting 1 |
Follow Jonathan Riess: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer Cetuximab, Osimertinib, Tucatinib - Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Not yet recruiting | Jonathan Riess | 36 | 2024-01-01 | 2023-10-05 |
| Pembrolizumab and Trametinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer and KRAS Gene Mutations Pembrolizumab, Trametinib - KRAS Gene Mutation, Metastatic Non-Squamous Non-Small Cell Lung Carcinoma | Phase 1 | Completed | Jonathan Riess | 15 | 2018-06-26 | 2025-05-21 |
| Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib Afatinib Dimaleate, Pembrolizumab - Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer | Phase 1 | Completed | Jonathan Riess | 11 | 2015-09-30 | 2024-10-16 |
Carcinoma, Non-Small-Cell Lung (3) · Lung Neoplasms (1)
pembrolizumab (2) · Afatinib (1) · Cetuximab (1) · osimertinib (1) · trametinib (1) · tucatinib (1)
United States (3)
Jonathan W Riess (1)
P30CA093373 (3)